The main finding of the present study is the observation that medium-term rosuvastatin clinical treatment is associated with reduced AT1R expression in monocytes of type 2 diabetic patients in the absence of AT2R expression changes. Here, AGTR1 is linked to type 2 diabetes mellitus.